Fundz

Iaso Biotherapeutics Secures $108 Million Series C Funding To Advance Global Development Of Innovative Cell Therapies

PRIVATESep 16, 2021

Amount Raised

$108 Million

Round Type

Series C

PleasantonBiotechnologyHealth CareScience And Engineering

Description

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicines, today announced the completion of $108 million Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases. The Series C round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital. Current shareholder GL Ventures also participated. Since its founding in 2017, IASO Bio has raised more than $178 million.

Quick answer

Iaso Bio raised $108 Million in a Series C round, dated September 16, 2021. Iaso Bio is based in Pleasanton, California, United States.

How much did Iaso Bio raise?
Iaso Bio raised $108 Million in a Series C round on September 16, 2021.
What does Iaso Bio do?
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases.
Where is Iaso Bio based and how big is it?
Iaso Bio is based in Pleasanton, California, United States.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Iaso Bio that raised within 45 days of this round, from Fundz verified event records.

  • Cardurion Pharmaceuticals raised an undisclosed amount on October 27, 2021.
  • Trait Biosciences Inc. raised $619K (Seed) on October 22, 2021.
  • American Bitcoin raised $18M on October 20, 2021.
  • Envisagenics raised $19M on October 19, 2021.
  • Abalos raised an undisclosed amount (Series A) on October 14, 2021.
  • MAIA Biotechnology raised $6.2M (Funding Round) on October 14, 2021.

Who to call at Iaso Bio, and when

A new round usually means Iaso Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Iaso Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Iaso Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Iaso Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Iaso Bio

Location

Pleasanton, California, United States

About

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 8 novel pipeline products, as well as IASO’s leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM), which was granted Breakthrough Therapeutic Designation by China’s National Medical Products Administration (NMPA) in February 2021. In addition. The company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021. For more information on IASO Bio, please visit www.iasobio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Iaso Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Iaso Bio's next move

See what Strategic adds

Iaso Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.